A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders

Table 1 Sample characteristics at baseline

Characteristics	DCS (n=34)	Placebo (n=33)	p-value
Demographics
Age (years), mean (SD)	8.38 (1.93)	8.25 (1.73)	.76
Sex, n (%) male	28 (82.35)	27 (81.82)	.95
Clinical Variables
Stanford-Binet V, mean (SD)
Full Scale IQ	92.42 (17.76)	87.30 (15.74)	.22
NonVerbal IQ	95.15 (18.03)	90.82 (15.19)	.30
Verbal IQ	90.85 (18.97)	85.45 (16.83)	.23
VABS-II Expressive Language subscale standard score, mean (SD)	87.38 (13.36)	84.55 (14.94)	.42
Clinical Global Impression-Severity	4.03 (0.18)	4.06 (0.24)	.58
Diagnosis, n (%)
PDD-NOS	12 (35.29)	15 (45.45)	.40
Autistic Disorder	3 (8.82)	5 (15.15)	.48^a
Asperger’s Disorder	19 (55.88)	13 (39.39)	.18
Concomitant medications, n (%)
Antipsychotics	8 (23.53)	8 (24.24)	.95
Alpha-2 Agonists	6 (17.65)	8 (24.24)	.51
Stimulants	14 (41.18)	11 (33.33)	.51
Sleep Aids	9 (26.47)	7 (21.21)	.61
Mood Stabilizers	1 (2.94)	2 (6.06)	.61^a
Glutamatergic Modulators	1 (2.94)	0 (0.00)	1.00^a
Other	3 (8.82)	1 (3.03)	.61^a
Concomitant treatment, n (%)
Speech Therapy	19 (55.88)	16 (51.52)	.72
Occupational Therapy	12 (35.29)	15 (45.45)	.40
Behavioral Therapy	9 (26.47)	9 (27.27)	.94
Other Psychotherapy	1 (2.94)	2 (6.06)	.61^a
Physical Therapy	0 (0.00)	2 (6.06)	.24^a
Social Skills Training	3 (8.82)	2 (6.06)	1.00^a
Music Therapy	0 (0.00)	1 (3.03)	.49^a
Other Treatments	3 (8.82)	0 (0.00)	.24^a

ISSN: 2040-2392